GOG-0207
Terminated
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)(IND #69,656, Sponsor-GOG)
Status
Terminated
Closed to Accrual & Treatment
September 25, 2012
Complete
March 2, 2017
Terminated
September 26, 2012
Disease Site
Gynecologic [GY] Cervix
Phase
II
Developmental Therapeutics
No
Primary Objective
To determine the efficacy of Celecoxib to induce complete remission (or partial regression to CIN 1) of CIN 2/3 or CIN 3 as evaluated in the post-treatment excisional biopsy.
To determine the toxicity of Celecoxib (400 mg once daily) as assessed by Common Terminology Criteria for Adverse Events in this patient population of women with CIN 2/3 or CIN 3.
Protocol Document
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
